Abstract. Sulindac sulfone (exisulind), is a promising anti-cancer agent because of its ability to induce apoptosis in a variety of malignant cell types and its minimal toxicity to normal cells. The induction of apoptosis is thought to account for the growth inhibitory effect of exisulind. The mitogen-activated protein kinase (MAPK) cascade has been implicated in the regulation of apoptosis in response to exisulind. With human SNU-C4 colon cancer cells that were much more resistant to exisulind than other colon cancer cells, in this study, we investigated whether the modulation of MAPK activity by using selective MAPK inhibitors can contribute to sensitizing SNU-C4 cells to exisulind. Exisulind (400 and 600 μM) slightly increased the phosphorylation of pERK1/2 but pretreatment with the pERK1/2 inhibitor PD98059 did not significantly change the apoptotic response of SNU-C4 cells. The same doses of exisulind increased the phosphorylation of p38MAPK, and pretreatment with the p38MAPK inhibitor SB203580 significantly potentiated growth inhibition and apoptosis induced by exisulind in SNU-C4 cells. We further found that apoptosis induced by a combination of exisulind and SB203580 was mediated through caspase activation. Collectively, our findings indicate that selective p38MAPK inhibitors potentiate apoptosis induction by exisulind in human SNU-C4 colon cancer cells. Such combinations may provide a more effective and less toxic strategy for the prevention or treatment of colon cancer.

Introduction

The nonsteroidal anti-inflammatory drug sulindac inhibits chemical carcinogenesis in rodents and causes the regression of adenomas in patients with familial adenomatous polyposis coli of the colon. Sulindac is intracellularly metabolized to a sulfide derivative with cyclooxygenase (COX) inhibitory activity as well as to a sulfone derivative without COX inhibitory activity. However, sulindac sulfone (exisulind) also induces apoptosis in a wide range of human tumor cell lines, but does not affect normal cells (1). Furthermore, it inhibits the growth of human prostate cancer cells in nude mice (2). In clinical trials, exisulind prevented colorectal polyp formation in patients with familial adenomatous polyposis. The induction of apoptosis is thought to be a major biological mechanism of growth inhibition by sulindac metabolites in cultured cells, animal models, and adenomas in patients with familial adenomatous polyposis.

The role of mitogen-activated protein kinase (MAPK) cascade has been implicated in signal transduction and the regulation of cell survival and death response to diverse external stimuli (3,4). The MAPK family is composed of three types of serine/threonine kinases: Extracellular signal-regulated kinases (ERKs), c-Jun NH2-terminal kinases (JNKs), and p38MAPK. These MAPKs mediate cellular responses to environmental stresses such as proinflammatory cytokines, UV light, γ-irradiation, growth factor withdrawal, ceramide, protein synthesis inhibitors, heat shock, osmotic shock, and anticancer drugs (3,5,6), and they have been implicated in the process of cell death in many cell types (7,8). Exisulind-induced apoptosis has been found to involve the inhibition of ERK1/2 in human colon cancer cells (9-11). In other studies, exisulind-induced apoptosis was shown to be mediated by JNK activation, which seems likely to be a downstream event of cellular cyclic GMP accumulation and the subsequent activation of the cyclic GMP-dependent protein kinase (12-14). The role of p38MAPK in regulating exisulind-induced apoptosis currently remains unclear but a recent study showing that a selective p38MAPK inhibitor potentiated apoptosis induction by sulindac sulfide suggests a plausible role of p38MAPK in mediating cellular response against sulindac analogues (15). We sought to investigate whether the modulation of MAPK activity by pharmacological MAPK inhibitors can sensitize exisulind-resistant SNU-C4 colon cancer cells to exisulind treatment. We provide experimental evidence that selective inhibitors of p38MAPK potentiated apoptosis induction by exisulind in human SNU-C4 colon cancer cells.
Materials and methods

Cell lines and cultures. The human HCT116 and LoVo colon cancer cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA), and the human SNU-C4 colon cancer cell line was purchased from the Korean Cell Line Bank (Seoul, Korea). Cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (HyClone, Logan, UT, USA) and 100 U/ml of both penicillin and streptomycin. Cells were grown in incubators at 37°C in a humid atmosphere of 95% air/5% CO₂.

Reagents and antibodies. Antibodies to human ß-actin and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) were obtained from Sigma (St. Louis, MO, USA). Exisulind was obtained from LKT Laboratories (St. Paul, MN, USA). SB203580 and PD98059 were purchased from Calbiochem (La Jolla, CA, USA). N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-FMK) was obtained from Enzyme System Products (Livemore, CA, USA). Antibodies to human poly(ADP-ribose) polymerase (PARP) were purchased from BD Pharmingen (San Diego, CA, USA), and the antibody to active caspase-3 was obtained from Cell Signaling Technology (Beverly, MA, USA). Phosphospecific and nonphosphospecific p38MAPK antibodies were obtained from New England Biolabs (Beverly, MA, USA). Phosphospecific and nonphosphospecific pERK1/2 antibodies were obtained from Cell signaling Technology. All other chemicals were of reagent grade and used without further purification.

Analysis of cell viability. Cells were seeded into 96-well plates. The following day, various doses of exisulind (diluted from a 500 mM stock in DMSO) or vehicle alone were added. The cells were then incubated for 48 h, and cell growth and viability were measured using MTT. The ability of cells to form formazan crystals by active mitochondrial respiration was determined using a microplate spectrophotometer (Molecular Devices) after dissolving the crystals in DMSO.

Assay of apoptosis. Following experimental treatments, the cell growth medium was harvested. After trypsinization, apoptotic bodies were collected by centrifugation, pooled with cells, and resuspended in Dulbecco's PBS. Histone-associated DNA fragments were quantified using a photometric enzyme immunoassay using the Cell Death Detection ELISA plus kit (Roche Applied Bioscience according to the manufacturer's protocol) (16).

Immunoblotting. Treated cells were collected by scraping, washed twice with PBS, and incubated for 15 to 30 min on ice in a lysis buffer containing 150 mM NaCl, 10 mM Tris, 0.2% Triton X-100, 0.3% NP-40, 0.2 mM Na₃VO₄, and protease inhibitors (Roche Diagnostics) (pH 7.4). Aliquots of cell lysates containing equal amounts of protein were denatured in SDS-reducing buffer by boiling for 5 min, resolved on SDS-polyacrylamide gels, and transferred to nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk and then probed with specific primary antibodies, followed by incubation with appropriate peroxidase-conjugated secondary antibodies. The blots were developed with ECL Plus reagent (Amersham, Arlington Heights, IL, USA) according to the manufacturer's protocol.

Statistical analysis. The significance of differences between the values obtained under different experimental conditions was determined using a two-tailed unpaired Student's t-test. Values of p<0.05 were considered statistically significant.

Results

Exisulind resistance in SNU-C4 cells. We first treated HCT116, LoVo and SNU-C4 colon cancer cells with increasing doses of exisulind for 48 h. We found that 100-800 μM exisulind dose-dependently inhibited the growth of HCT116 and LoVo cells, but not SNU-C4 cells (Fig. 1A). Therefore, the dose of exisulind resulting in 50% inhibition of growth was ~450 and 700 μM in SNU-C4 cells, but even higher than 1000 μM in SNU-C4 cells.
extent of apoptosis in exisulind-resistant SNU-C4 cells with the most sensitive HCT116 cells. Analysis of DNA fragmentation revealed that exisulind doses that induce growth inhibition in HCT116 cells but not in SNU-C4 cells (400 and 600 μM) caused a dose-dependent induction of apoptosis in HCT116 cells but not in SNU-C4 cells (Fig. 1B). In addition, exisulind caused morphological changes, including cell shrinkage and chromatin condensation, in HCT116 cells but not in SNU-C4 cells (data not shown). These results indicate that SNU-C4 cells are resistant to exisulind-induced apoptosis.

Effect of pERK1/2 inhibitors on exisulind response in SNU-C4 cells.

To investigate the role of pERK1/2 in exisulind-induced apoptosis, we monitored the dose-dependent changes in pERK1/2 phosphorylation, which reflects its enzyme activity. When SNU-C4 cells were treated with 400 or 600 μM exisulind for 24 h, the phosphorylation of pERK1/2 was slightly increased by 600 μM exisulind (Fig. 2A). Pretreatment with a pERK1/2 inhibitor PD98059 did not affect the growth inhibition (Fig. 2B) and apoptosis (Fig. 2C) induced by 600 μM exisulind. Our data suggest that pERK1/2 inhibition is not sufficient to sensitize SNU-C4 cells to exisulind-induced apoptosis.

Effect of p38MAPK inhibitors on exisulind response in SNU-C4 cells.

To investigate the role of p38MAPK in exisulind-induced apoptosis, we monitored the dose-dependent changes in p38MAPK phosphorylation. Exisulind (400 and 600 μM) caused a dose-dependent increase in the phosphorylation of p38MAPK, suggesting the activation of this protein kinase. In contrast, in exisulind-sensitive HCT116 cells, 600 μM exisulind caused a significant decrease in the level of phosphorylated p38MAPK without changes in its expression (Fig. 3A). To further investigate the role of p38MAPK in exisulind-induced apoptosis, we pretreated cells with the p38MAPK inhibitor SB203580. This inhibitor significantly augmented exisulind-induced growth inhibition and apoptosis in SNU-C4 cells (Fig. 3B and C). These data suggest that p38MAPK inhibition can sensitize SNU-C4 cells to exisulind treatment.

Caspase dependency in mediating apoptosis induced by exisulind and SB203580.

Exisulind-induced apoptosis has been shown to involve the activation of the caspase cascade (10,17). We therefore examined whether apoptosis induced by exisulind in combination with SB203580 involved caspase activation by measuring the conversion of procaspase-3 to its catalytically active form (p17/p19). The catalytically active form of caspase-3 was evident in exisulind-treated SNU-C4 cells only when they were treated with the exisulind and SB203580 combination (Fig. 4A). We also detected the 85-kDa PARP fragment, a general marker of caspase-dependent apoptosis, only when SNU-C4 cells were treated with both exisulind and SB203580 for 48 h (Fig. 4A). Finally, we found that pretreatment with a general caspase inhibitor z-VAD-FMK significantly blocked the apoptosis induced by the exisulind and SB203580 combination (Fig. 4B). Therefore, it seems likely that apoptosis induced by combination treatment with exisulind and SB203580 is mediated through caspase activation.

Discussion

Exisulind reduces cell viability and induces apoptosis that may be critical to its anticancer effects. Earlier studies have shown that the modulation of MAPK pathways is involved in the regulation of the apoptotic response of cells to exisulind, and that the inhibition of ERK1/2 activity by pharmacological inhibitors augmented the exisulind-induced apoptosis in human HCT116 colon cancer cells (9). Our present data suggest that the pERK1/2 inhibitor PD98059 was ineffective in increasing the apoptotic susceptibility of SNU-C4 cells, suggesting that the role of the MAPK pathway in exisulind-induced apoptosis may differ depending on the cellular context as well as cell types. To date, the role of p38MAPK in exisulind-induced apoptosis remains unknown. Here we
observed the dose-dependent increase in the phosphorylation of p38MAPK by exisulind treatment. HCT116 and SNU-C4 cells were treated with indicated concentrations of exisulind. At 24-h postincubation, cellular lysates were obtained and subjected to immunoblot analysis to detect phosphoactive forms of p38MAPK. (B) With or without 1-h pretreatment with 20 μM SB203580, SNU-C4 cells were treated with 600 μM exisulind for 48 h, and then subjected to MTT assay. Results are expressed as the percentage growth relative to control (DMSO) cells. (C) Apoptosis was quantified by an ELISA that specifically detected histone-associated DNA. With or without 1-h pretreatment with 20 μM SB203580, cells were treated with 600 μM exisulind for 48 h. The bar represents the ratio of the absorbance at 405 nm in cells incubated with exisulind, SB203580 or exisulind plus SB203580, and that in control (DMSO) cells (mean±SD of two experiments performed in triplicate) [*p<0.01 by unpaired t-test, compared with control (DMSO) cells].

The mechanism by which p38MAPK modulates apoptosis is poorly understood. Depending on the apoptotic stimuli and the cellular context, p38MAPK has been suggested to have an antiapoptotic and protective role. p38MAPK activation contributed to the execution of apoptosis in response to certain types of agents, such as the tumor necrosis factor-alpha (18), zinc (19), and sodium arsenite (20). On the contrary, the inhibition of p38MAPK was involved in staurosporine-induced apoptosis (21), and p38MAPK inhibitors promoted TNF-alpha-induced apoptosis in human myelomonocytic leukemia cells (22). Our results do not establish how the inhibition of p38MAPK leads to caspase activation, PARP cleavage, and execution of the apoptotic process in exisulind-resistant SNU-C4 cells. A recent study, however, showed that the inhibition of p38MAPK can inhibit the expression of Bcl-2 and sensitize cells to drug-induced apoptosis, suggesting that p38MAPK plays a key role in drug resistance (23,24). Therefore, we speculate that p38MAPK regulates the expression of antiapoptotic proteins such as Bcl-2 in exisulind-treated colon cancer cells and, that the
pharmacological inhibition of p38MAPK also leads to the decreased expression of antiapoptotic proteins in exisulind-resistant SNU-C4 cells. Further studies are needed, however, to test the validity of this hypothesis.

Previous studies have shown that JNK activation is a major mediator of exisulind-induced apoptosis (12,14). The inhibition of p38MAPK has been shown to be linked to JNK activation in staurosporine-induced apoptosis (21). Therefore, we tested whether the enhancement of exisulind-induced apoptosis by SB203580 is associated with an increased activation of JNK. However, we did not observe a significant increase in JNK activation under these conditions (data not shown), suggesting that the molecular pathway by which exisulind causes apoptosis may be different under conditions where p38MAPK is inhibited.

Recently, considerable attention has been focused on the use of combinations of anticancer agents for prevention or enhanced efficacy. Such combinations can lower the necessary doses of each agent, reducing their toxicity. Attempts have been made to test the interaction of exisulind with other anticancer agents. For example, exisulind has been shown to exert a synergistic anticancer effect when used in combination with the proteasome inhibitor bortezomib (25), the green tea component epigallocatechin gallate (26), and chemotherapeutic drugs including docetaxel (27) and cisplatin (28). Therefore, our results may provide a molecular basis for the rational design of combination strategies using exisulind and agents that reduce p38MAPK activity for the prevention and treatment of colon cancer.

Acknowledgements

This study was supported by a research grant from the National Cancer Center 0310010-3.

References